Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 13/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26099956 | 0.90 | TYK2 (0.43) | TYK2PDE4D | |
| Trifluoroacetic Acid SCHEMBL30392530 | 0.87 | TYK2 (0.40) | TYK2PDE4D | |
| SCHEMBL26100155 | 0.87 | TYK2 (0.46) | TYK2PDE4D | |
| SCHEMBL31161473 | 0.86 | TYK2 (0.38) | TYK2PDE4DUSP30 | |
| SCHEMBL31161947 | 0.86 | TYK2 (0.37) | TYK2USP30 | |
| SCHEMBL31161463 | 0.86 | TYK2 (0.37) | TYK2USP30 | |
| SCHEMBL31161557 | 0.84 | TYK2 (0.36) | TYK2USP30 | |
| SCHEMBL26100325 | 0.83 | TYK2 (0.49) | TYK2PDE4D | |
| SCHEMBL30392419 | 0.83 | TYK2 (0.49) | TYK2PDE4D | |
| SCHEMBL31161444 | 0.83 | TYK2 (0.36) | TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| EP-4423086-A1 | TYK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023076161-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076161-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, DYRK2, DYRK1A | TYK2 1/4885GPR119 3223/4885UCHL1 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.